Ph.D., Chief Scientific Officer, ACT Genomics
Dr. Shu-Jen Chen currently leads the sequencing group and bioinformatics group at ACT Genomics, with a focus on developing biomarkers for cancer diagnosis and for treatment prediction. She specializes in automated drug screening system, cancer biology, genomics and transcriptomics technologies, omics data analysis and biological database integration. Dr. Chen received her Ph.D. degree in Biochemistry from Virginia Commonwealth University, did her Postdoctoral training at Baylor College of Medicine, and was a Research Assistant Professor at SUNY Buffalo. In 1998, she joined National Health Research Institute (NHRI) as an Assistant Investigator and established the high throughput screening program for the institute. Dr. Chen joined TaiGen in 2001 to lead the in vitro pharmacology group. In 2006, she moved to Chang Gung University as an Associate Professor of the Department of Biomedical Sciences, and built up the microarray and NGS platforms for the Molecular Medicine Research Center.
Immunotherapy Showcase: ACT Genomics
Founded in 2014, ACT Genomics is a molecular diagnostics company committed to turning genomic data into actionable cancer solutions.
Biomarker Solution For Immunotherapy: TMB And Beyond
Biomarker solutions for immune checkpoint inhibitors: ACTOnco (NGS-based) detects all somatic alternations and TMB (evaluated in FOCR TMB harmonization program). Another novel chip-based assay determines multiple RNA expression levels for tumor microenvironment using FFPE tissue.